NHANES 2009-2012 findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men

Cancer Research

Volumn 75, Issue 12, 2015, Pages 2468-2477

  Chaturvedi, Anil K ^a   Graubard, Barry I ^a   Broutian, Tatevik ^b   Pickard, Robert K L ^b   Tong, Zhen Yue ^b   Xiao, Weihong ^b   Kahle, Lisa ^c   Gillison, Maura L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SEXUAL BEHAVIOR; SMOKING; UNITED STATES; VIRUS DETECTION; VIRUS LOAD; ISOLATION AND PURIFICATION; MIDDLE AGED; MOUTH DISEASES; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEXUALITY; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; UNITED STATES; YOUNG ADULT;

EID: 84930684935     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2843     Document Type: Article

References (39)

1. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
3. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9.
4. Hong AM, Grulich AE, Jones D, Lee CS, Garland SM, Dobbins TA, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010;28:3269-72.
5. Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010;16:1671-7.
6. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31:4550-9.
7. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693-703.
8. Sanders AE, Slade GD, Patton LL. National prevalence of oralHPVinfection and related risk factors in the U. S. adult population. Oral Dis 2012;18:430-41.
9. D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 2014;9:e86023.
10. Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirusrelated cancer incidence by gender and anatomic site of infection. Int J Cancer. 2014 Jul. 17. [Epub ahead of print].
11. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U S Department of Health and Human Services, Centers for Disease Control and Prevention, 2014.
12. Munoz N, Bosch FX, De SS, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
14. Korn EL, Graubard BI. (1999) Wiley series in probability and statistics, in analysis of health surveys. John Wiley & Sons, Inc., Hoboken, NJ.
15. Assmann SF, Hosmer DW, Lemeshow S, Mundt KA. Confidence intervals for measures of interaction. Epidemiology 1996;7:286-90.
16. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61.
17. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
18. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007;99:1801-10.
19. Beachler DC, D'Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013;208:330-9.
20. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008;14:888-94.
21. Nyitray AG, Lin HY, Fulp WJ, Chang M, Menezes L, Lu B, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis 2014;209:1007-15.
22. Klein SL. The effects of hormones onsex differences in infection: from genes to behavior. Neurosci Biobehav Rev 2000;24:627-38.
23. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200:1059-67.
24. Edelstein ZR, Carter JJ, Garg R, Winer RL, Feng Q, Galloway DA, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis 2011;204:209-16.
25. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection inmen (HIM): a cohort study. Lancet 2011;377:932-40.
26. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011;204:566-73.
27. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012;72:676-85.
28. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010;102:1653-62.
29. Wilson L, Pawlita M, Castle PE, Waterboer T, Sahasrabuddhe V, Gravitt PE, et al. Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 2014;210:448-55.
30. Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, Van Diemen PM, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005;41:612-20.
31. Chaturvedi AK, Graubard BI, Pickard RK, Xiao W, Gillison ML. High-Risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis 2014;210:441-7.
32. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20.
33. Kissinger P, Rice J, Farley T, Trim S, Jewitt K, Margavio V, et al. Application of computer-assisted interviews to sexual behavior research. Am J Epidemiol 1999;149:950-4.
34. Wadsworth J, Johnson AM, Wellings K, Field J. What's in a mean? - an examination of the inconsistency between men and women reporting sexual partnerships. J R Stat Assoc 1996;159:111-23.
35. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
36. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
37. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012;5:18-23.
38. National Cancer Institute. Accelerating HPV vaccine uptake: urgency for action to prevent cancer. A Report to the President of the United States from the President's Cancer Panel.. Bethesda, MD; 2014.
39. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother 2014;10:2109-11.